Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 323,662
  • Shares Outstanding, K 82,778
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,600 K
  • EBIT $ -140 M
  • EBITDA $ -145 M
  • 60-Month Beta 1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.36

Options Overview Details

View History
  • Implied Volatility 162.26% (-133.11%)
  • Historical Volatility 75.13%
  • IV Percentile 26%
  • IV Rank 8.51%
  • IV High 807.24% on 05/15/25
  • IV Low 102.26% on 03/27/25
  • Expected Move (DTE 16) 2.21 (56.96%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 16,321
  • Open Int (30-Day) 24,059
  • Expected Range 1.67 to 6.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 6
  • High Estimate -0.09
  • Low Estimate -0.65
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +4.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +24.04%
on 12/02/25
4.15 -6.75%
on 12/15/25
+0.33 (+9.32%)
since 11/28/25
3-Month
3.12 +24.04%
on 12/02/25
5.00 -22.55%
on 10/06/25
+0.64 (+19.81%)
since 09/30/25
52-Week
1.61 +140.37%
on 04/09/25
5.37 -27.93%
on 09/26/25
-0.04 (-1.02%)
since 12/30/24

Most Recent Stories

More News
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,...

LRMR : 3.87 (-1.02%)
Larimar: Q3 Earnings Snapshot

Larimar: Q3 Earnings Snapshot

LRMR : 3.87 (-1.02%)
Larimar Therapeutics Reports Third Quarter 2025 Financial Results

In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement...

LRMR : 3.87 (-1.02%)
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting...

LRMR : 3.87 (-1.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors...

LRMR : 3.87 (-1.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors...

LRMR : 3.87 (-1.02%)
The Best AI for Picking Stocks, Ranked by Performance

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

SOUN : 9.97 (-0.70%)
SMCI : 29.19 (-1.55%)
HUT : 46.11 (-0.37%)
MLTX : 13.16 (-0.38%)
LRMR : 3.87 (-1.02%)
REPL : 9.94 (+1.22%)
ASTS : 72.69 (-2.66%)
RGC : 21.25 (-7.21%)
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations...

LRMR : 3.87 (-1.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors...

LRMR : 3.87 (-1.02%)
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

LOS ANGELES , Oct. 16, 2025 /PRNewswire/ --  The DJS Law Group  announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company")...

LRMR : 3.87 (-1.02%)

Business Summary

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

See More

Key Turning Points

3rd Resistance Point 4.11
2nd Resistance Point 4.04
1st Resistance Point 3.98
Last Price 3.87
1st Support Level 3.85
2nd Support Level 3.78
3rd Support Level 3.72

See More

52-Week High 5.37
Fibonacci 61.8% 3.93
Last Price 3.87
Fibonacci 50% 3.49
Fibonacci 38.2% 3.05
52-Week Low 1.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar